Pathology and Therapeutics of COVID-19: A Review
COVID-19 pandemic has taken over the world. Spreading form its epicenter in a seafood market in Wuhan to more than 200 countries, it has caused alarming situations. The viral infection is caused by an RNA virus called SARS-CoV-2. Its genome resembles the SARS-CoV-1 and MERS-CoV genome. COVID-19 cases were first reported in December 2019 in China; it affects the lungs causing mild to severe respiratory disease. No antiviral drug for the infection has been approved yet, but certain drugs are under consideration including Chloroquine, Hydroxychloroquine and Teicoplanin. The review article will first present the structure of the SARS-CoV-2 and compare it to SARS-CoV-1 and MERS-CoV. The article will then highlight its effect on different organs. Finally, it will highlight the therapeutics which are in consideration and which are being used. The article will provide a good insight into the COVID-19 infection.
2. Huang, Chaolin & Wang, Yeming & Li, Xingwang & Ren, Lili & Zhao, Jianping & Hu, Yi & Zhang, Li & Fan, Guohui & Xu, Jiuyang & Gu, Xiaoying & Cheng, Zhenshun & Yu, Ting & Xia, Jiaan & Wei, Yuan & Wu, Wenjuan & Xie, Xuelei & Yin, Wen & Li, Hui & Liu, Min & Cao, Bin. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395. 10.1016/S0140-6736(20)30183-5. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD: Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL; 2020.
3. Gordon, Calvin & Tchesnokov, Egor & Feng, Joy & Porter, Danielle & Gotte, Matthias. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry. jbc.AC120.013056. 10.1074/jbc.AC120.013056.
4. Seah, Ivan & Agrawal, Rupesh. (2020). Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocular Immunology and Inflammation. 1-5. 10.1080/09273948.2020.1738501.
5. Li, Xiaowei & Manman, Geng & Peng, Yizhao & Meng, Liesu & Lu, Shemin. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 10.1016/j.jpha.2020.03.001.
6. Cui, Jie & Li, Fang. (2018). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 17. 10.1038/s41579-018-0118-9.
7. Xu, Zhe & Shi, Lei & Wang, Y. & Zhang, Jiyuan & Huang, Lei & Zhang, Chao & Liu, Shuhong & Zhao, Peng & Liu, Hongxia & Zhu, Li & Tai, Yanhong & Bai, Changqing & Gao, Tingting & Song, Jin-Wen & Xia, Peng & Dong, Jinghui & Zhao, Jingmin & Wang, Fu-Sheng. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 10.1016/S2213-2600(20)30076-X.
8. Zhang, Chao & Shi, Lei & Wang, Fu-Sheng. (2020). Liver injury in COVID-19: management and challenges. The lancet. Gastroenterology & hepatology. 10.1016/S2468-1253(20)30057-1.
9. Mao, Ling & Wang, Mengdie & Chen, Shanghai & He, Quanwei & Chang, Jiang & Hong, Candong & Zhou, Yifan & Wang, David & Li, Yanan & Jin, Huijuan & Hu, Bo. (2020). Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. 10.1101/2020.02.22.20026500.
10. Zheng, Ying-Ying & Ma, Yi-Tong & Zhang, Jin-Ying & Xie, Xiang. (2020). COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 1-2. 10.1038/s41569-020-0360-5.
11. Devaux, Christian & Rolain, Jean-Marc & Colson, Philippe & Raoult, Didier. (2020). New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International journal of antimicrobial agents. 105938. 10.1016/j.ijantimicag.2020.105938.
12. Baron, Sophie & Devaux, Christian & Colson, Philippe & Raoult, Didier & Rolain, Jean-Marc. (2020). Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. International Journal of Antimicrobial Agents. 105944. 10.1016/j.ijantimicag.2020.105944.
13. Lescure, Francois-Xavier & Bouadma, Lila & Nguyen, Duc & Parisey, Marion & Wicky, Paul-Henri & Behillil, Sylvie & Gaymard, Alexandre & Bouscambert-Duchamp, Maude & Donati, Flora & Le Hingrat, Quentin & Enouf, Vincent & Houhou, Nadhira & Valette, Martine & Mailles, Alexandra & Lucet, Jean-Christophe & Mentre, France & Duval, Xavier & Descamps, Diane & Malvy, Denis & Yazdanpanah, Yazdan. (2020). Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases. 10.1016/S1473-3099(20)30200-0. Ni, Li & Zhou, Ling & Zhou, Min & Zhao, Jianping & Wang, Dao. (2020). Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Frontiers of Medicine. 10.1007/s11684-020-0757-x.
14. Caly, Leon & Druce, Julian & Catton, Mike & Jans, David & Wagstaff, Kylie. (2020). The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 104787. 10.1016/j.antiviral.2020.104787.
15. Jiang, Xuan & Rayner, Simon & Luo, Min-Hua. (2020). Does SARS‐CoV‐2 has a longer incubation period than SARS and MERS?. Journal of Medical Virology. 92. 10.1002/jmv.25708.
16. Prompetchara, Eakachai & Ketloy, Chutitorn & Palaga, Tanapat. (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific journal of allergy and immunology. 38. 10.12932/AP-200220-0772.
17. Cortegiani, Andrea & Ingoglia, Giulia & Ippolito, Mariachiara & Giarratano, Antonino named Antonello & Einav, Sharon. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care. 10.1016/j.jcrc.2020.03.005.
18. Hassan S, Sheikh F N, Jamal S, et al. (March 21, 2020) Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus 12(3): e7355. doi:10.7759/cureus.7355
19. Guo, Yan-Rong & Cao, Qing-Dong & Hong, Zhong-Si & Tan, Yuan-Yang & Chen, Shou-Deng & Jin, Hong-Jun & Tan, Kai-Sen & Wang, De-Yun & Yan, Yan. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 7. 10.1186/s40779-020-00240-0.
20. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020 Feb;35(6):e79. https://doi.org/10.3346/jkms.2020.35.e79
21. https://www.worldometers.info/coronavirus/ [Last accessed on 6th April 2020 at 21:00].
Copyright (c) 2020 Haleema Anwar, Qudsia Umaira Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to firstname.lastname@example.org
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to email@example.com